Wall Street brokerages expect that Aldeyra Therapeutics Inc (NASDAQ:ALDX) will report earnings per share (EPS) of ($0.32) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Aldeyra Therapeutics’ earnings. The lowest EPS estimate is ($0.33) and the highest is ($0.30). Aldeyra Therapeutics reported earnings per share of ($0.36) during the same quarter last year, which suggests a positive year over year growth rate of 11.1%. The business is expected to issue its next earnings report on Thursday, March 29th.
On average, analysts expect that Aldeyra Therapeutics will report full-year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.37) to ($1.33). For the next year, analysts anticipate that the business will post earnings of ($1.43) per share, with EPS estimates ranging from ($1.53) to ($1.24). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Aldeyra Therapeutics.
ALDX has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “buy” rating and set a $6.75 target price for the company in a research report on Tuesday, November 14th. Seaport Global Securities restated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Thursday, March 1st. ValuEngine upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $27.00 price objective on shares of Aldeyra Therapeutics in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $16.79.
Aldeyra Therapeutics (NASDAQ:ALDX) traded down $0.15 during midday trading on Wednesday, reaching $8.70. 27,758 shares of the company’s stock traded hands, compared to its average volume of 105,301. Aldeyra Therapeutics has a 1 year low of $3.80 and a 1 year high of $11.90. The company has a current ratio of 20.35, a quick ratio of 20.35 and a debt-to-equity ratio of 0.02. The company has a market cap of $170.15, a PE ratio of -6.21 and a beta of 0.46.
Institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new position in shares of Aldeyra Therapeutics in the third quarter valued at approximately $134,000. Woodstock Corp boosted its holdings in shares of Aldeyra Therapeutics by 20.4% in the fourth quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock valued at $396,000 after acquiring an additional 9,850 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 34.6% in the fourth quarter. Geode Capital Management LLC now owns 102,263 shares of the biotechnology company’s stock valued at $695,000 after acquiring an additional 26,269 shares in the last quarter. Mangrove Partners bought a new position in shares of Aldeyra Therapeutics in the fourth quarter valued at approximately $1,118,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after acquiring an additional 9,407 shares in the last quarter. Institutional investors and hedge funds own 51.17% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Aldeyra Therapeutics Inc (ALDX) Expected to Announce Earnings of -$0.32 Per Share” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://ledgergazette.com/2018/03/21/aldeyra-therapeutics-inc-aldx-expected-to-announce-earnings-of-0-32-per-share.html.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.